Sipuleucel-T: immunotherapy for advanced prostate cancer.

Open Access J Urol · 2011 · PMC3818937 · PMID 24198636

Europe PMC DOI

hedged sentences

0.0800

closest p · 1.6× alpha

0.0800

boldest claim

The sentences

showed a trendP = 0.08so close (0.05 < p ≤ 0.1)

In contrast with what had been observed in earlier-phase studies, no significant correlation was found between the detection of T-cell proliferative responses to either PA2024 or PAP and the overall survival of these patients (nor antibodies to PAP, although this showed a trend towards correlation with survival, P = 0.08).

also in 53,322 other papers

did not reach statistical significanceno p-value reported

62 However, while the authors detected serum PSA decreases of greater than 25% in 6.8% of patients receiving sipuleucel-T, the primary endpoint of time to disease progression did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.